PD-1抑制剂联合化疗治疗转移性鼻咽癌1例  

PD-1 inhibitor combined with chemotherapy in the treatment of metastatic nasopharyngeal carcinoma:a case report

作　　者：程艳双 王娟[1] 金洁莹 吴求吉[2] 钟亚华[1] CHENG Yanshuang;WANG Juan;JIN Jieying;WU Qiuji;ZHONG Yahua(Department of Head,Neck and Pediatric Oncology Radiotherapy and Chemotherapy,Zhongnan Hospital of Wuhan University,Wuhan 430071,China;Department of Gynecological Oncology Radiotherapy and Chemotherapy,Zhongnan Hospital of Wuhan University,Wuhan 430071,China)

机构地区：[1]武汉大学中南医院头颈与儿童肿瘤放化疗科,武汉430071 [2]武汉大学中南医院妇科肿瘤放化疗科,武汉430071

出　　处：《数理医药学杂志》2024年第5期392-397,共6页Journal of Mathematical Medicine

摘　　要：本文回顾性分析了一例晚期鼻咽癌(nasopharyngeal carcinoma,NPC)伴多发肝、肺、淋巴结转移患者的诊治过程。患者接受卡瑞利珠单抗免疫治疗联合化疗后显示出良好的疗效,无进展生存期为55个月。即使治疗期间因新冠疫情中断免疫治疗5个月,患者肿瘤仍得到有效控制,无明显复发转移征象。治疗期间无3~4级治疗相关不良反应,患者生活质量良好。对于复发/转移性NPC,免疫治疗联合化疗给患者带来了显著的生存获益。This paper retrospectively analyzed the diagnosis and treatment process of a patient with advanced nasopharyngeal carcinoma(NPC)accompanied by multiple liver,lung,and lymph node metastases.The patient underwent camrelizumab immunotherapy in conjunction with chemotherapy,and demonstrated positive efficacy with a progression-free survival of 55 months.Despite a 5-month interruption in immunotherapy treatment caused by the COVID-19 epidemic,the patient's tumor remained well controlled with no apparent signs of recurrence or metastasis.Throughout the treatment,there were no grade 3-4 treatment-related side effects,and the patient's quality of life remained good.Immunotherapy combined with chemotherapy can bring significant survival benefits to patients with the recurrent/metastatic NPC.

关 键 词：鼻咽癌 PD-1抑制剂 免疫治疗 化疗 

分 类 号：R739.63[医药卫生—肿瘤]